Recent Advances in Multiple Myeloma: Applying Real-World Evidence to Clinical Practice - Episode 3

Triplet vs Doublet Induction Therapy for Transplant-Ineligible MM and Role of Real-World Evidence

,

A key opinion leader explains whether doublet regimens still have a place in transplant-ineligible multiple myeloma treatment.

EP. 1: Frontline Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
EP. 2: Comparison of Results from the MAIA and SWOG0777 Studies
Now Viewing
EP. 3: Triplet vs Doublet Induction Therapy for Transplant-Ineligible MM and Role of Real-World Evidence
EP. 4: Treatment Decision-Making Based on Real-World Data in Transplant-Ineligible NDMM
EP. 5: Maintenance Therapy in Transplant-Ineligible Multiple Myeloma
EP. 6: Determining Treatment Duration for Transplant-Ineligible Multiple Myeloma
EP. 7: Unmet Needs of Transplant-Ineligible Multiple Myeloma
EP. 8: Racial Disparities in the Treatment of Multiple Myeloma Patients
EP. 9: Comparing Combination Treatment Regimens in Transplant-Eligible NDMM
EP. 10: Is There a Role for MRD-Response Adapted Therapy in Transplant-Eligible NDMM?
EP. 11: The GMMG HD7 Trial of Isa-VRd vs VRd in Transplant-Eligible NDMM
EP. 12: Treatment Decision-Making Based on Clinical Trial Data in Transplant-Eligible NDMM
EP. 13: Treatment Decision-Making Based on Real-World Data in Transplant-Eligible NDMM
EP. 14: Measuring Treatment Response in Transplant-Eligible NDMM after Induction Therapy